Tissue Factor Science

Iconic Therapeutics is leveraging its deep insight into the role of tissue factor in inflammation and angiogenesis to develop breakthrough medicines for ophthalmology and oncology indications.

Learn More

With our investigational tissue factor therapeutics, we are pursuing promising opportunities to modify grievous diseases in ophthalmology, including wet age-related macular degeneration (AMD).


While tissue factor (TF) overexpression itself is not oncogenic, it facilitates key processes that lead to the development and progression of tumors. We are exploring potential therapeutic agents that target TF across a broad range of solid tumors.

Recent News

August 22, 2019: Iconic Therapeutics Signs Ophthalmology Option Agreement

May 16, 2019: Iconic Therapeutics and Exelixis enter into an exclusive option and license agreement for ICON-2

May 14, 2019: Iconic Therapeutics Enters Licensing Agreement with Zymeworks for ZymeLinkTM Antibody-Drug Conjugate Platform

Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines for serious diseases. Our deep understanding of the role of Tissue Factor (TF) in angiogenesis, inflammation, and cancer has allowed us to develop a unique therapeutic approach to retinal disease and oncology. Led by a seasoned management team, Iconic is advancing its lead candidate, ICON-1, through clinical development for the treatment of wet AMD and is progressing its pre-clinical oncology program towards IND.


Tissue Factor

Learn more >

Wet AMD Program

Learn more >